Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea

Jeon, Minji; Kim, Jehun; Oh, Chi Eun; Lee, Jin Young

doi:10.3390/vaccines9101096

Cited by 20 publications

(20 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is supported by another study conducted in Korea where the pain, injection site tenderness, and fatigue were the top adverse events of health professionals experienced. 32 It is also supported by findings of other studies on health professionals from Togo, 31 and Nepal. 34 Compared to other brands of COVID-19 vaccines, ChAdOx1 had a lower AEFI than Moderna (94%) but higher AEFI than Pfizer vaccine (53%).…”

Section: Discussionsupporting

confidence: 69%

“…On the other side, the magnitude of AEFI was lower than web-based study findings from Korea where more than 90% of the health professionals reported at least one AEFI. 32 This might be due to variations of outcome ascertainment techniques. Accordingly, the Korean study was a mobile-based daily report from the participants while we collected the data from the respondents a week after they took the vaccine, which may lead to missing mild symptoms.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

More Than Three-Fourths of AstraZeneca (ChAdox1 COV-19) COVID-19 Vaccinated Individuals Develop Post Immunization Adverse Event in Northwest Ethiopia

Muluneh¹,

Merid²,

Alemu³

et al. 2022

IDR

View full text Add to dashboard Cite

Background Ethiopia was using the ChAdOx1 COV-19 vaccine, and health professionals were targets of the first phase of the vaccination strategy. Evidence on the adverse events following immunization (AEFI) was barely available. The study aimed to assess the magnitude and associated factors of adverse events following ChAdOx1 COV-19 immunization among health professionals of the University of Gondar Specialized and Comprehensive Hospital, 2021. Methods An institution-based cross-sectional study was conducted among health professionals of the University of Gondar Comprehensive and specialized referral hospital. All health professionals who took the ChAdOx1 COV-19 vaccine in the 1st phase were surveyed. A total of 314 health professionals who took the ChAdOx1 COV-19 vaccine were included. The EpiData version 4.6.0.0 and Stata 16 were used for data entry and analysis, respectively. A binary logistic regression was used to identify statistically significant factors associated with AEFI. Chi-square and multicollinearity assumptions were tested. A p-value <0.2 and 0.05 were used as cut-off values of significance in the bi- and multivariable logistic regression models, respectively. An adjusted odds ratio (AOR) with 95% CI was reported for statistically significant variables. Results Among 314 study participants, 263 of them had at least one mild to severe AEFI of ChAdOx1 COV-19 with a prevalence of AEFI of 83.76% (95% CI: 79.23, 87.46). The commonest AEFI observed were injection site tenderness (n=198/263), fatigue (114/263), headache (n=107/263), and muscle pain (n=85/263). Females (AOR=2.75, 95% CI: 1.15, 6.58), and participants who felt the vaccine was unsafe (AOR=2.84, 95% CI: 1.03, 7.85) were having nearly three times more odds of AEFI immunization as compared to males and those who felt the vaccine was safe, respectively. Conclusion Adverse event following immunization has been a public health problem in Northwest Ethiopia. Being female and having a feeling that the vaccine is unsafe were statistically significantly associated with AEFI.

show abstract

Section: Discussionsupporting

confidence: 69%

Section: Discussionmentioning

confidence: 99%

More Than Three-Fourths of AstraZeneca (ChAdox1 COV-19) COVID-19 Vaccinated Individuals Develop Post Immunization Adverse Event in Northwest Ethiopia

Muluneh¹,

Merid²,

Alemu³

et al. 2022

IDR

View full text Add to dashboard Cite

show abstract

“…The most common local side effects in this study was injection site pain (39%), followed by arm pain (25.4%), and injection site swelling (2.5%) and itching (2.5%). However, these side effects emerged generally with low frequencies than previously reported, especially with the adenoviral vector vaccines, i.e., AZD1222 where injection site pain was reported with a prevalence higher than 58% ( 24 , 27 , 47 – 49 ). Similarly, a large-scale multinational study covering more than 10,000 vaccinees in the Arab countries reported that more than 58% of the participants suffered from injection site pain and swelling ( 50 ).…”

Section: Discussionmentioning

confidence: 69%

“…The local and systemic side effects were more prevalent after the second dose than the first dose for both inactivated and adenoviral vector vaccines, thus, confirming what was previously reported in different studies ( 45 , 46 ). Contrarily, Omeish et al 2021 in Jordan and Jeon et al 2021 in Korea found that side effects were more frequent and more severe after the first dose ( 18 , 47 ).…”

Section: Discussionmentioning

confidence: 97%

Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers

Lounis

Rais

Bencherit

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

Healthcare workers were prioritized in vaccination campaigns globally because they are exposed to the highest risk of contamination by SARS-CoV-2. This study evaluated the self-reported post-vaccination side effects of inactivated (BBIBP-CorV and CoronaVac) and adenoviral vector-based (AZD1222, Gam-COVID-Vac and Ad26.COV2.S) vaccines among Algerian healthcare workers using a validated questionnaire. The final analysis included 721 healthcare workers, with a predominance of females (59.1%) and younger individuals 20–30 years old (39.4%). Less than half (49.1%) of the respondents reported at least one local side effect, while 53.8% reported at least one systemic side effect. These side effects were more prevalent among viral vector vaccinees than inactivated virus vaccinees. The most common local side effects were injection site pain (39%) and arm pain (25.4%), while fatigue (34.4%), fever (28.4%), headache (24.8%) and myalgia (22.7%) were the most prevalent systemic side effects. The side effects appeared earlier among inactivated virus vaccines recipients and generally lasted for 2 to 3 days for the two vaccinated groups. The risk factors associated with a higher prevalence of side effects included female gender, allergic individuals, individuals with regular medication, those who contracted the COVID-19 disease and those who received two doses for both inactivated and viral-based vaccines groups. Despite the higher prevalence of post-vaccination side effects among adenoviral vector vaccines recipients, both vaccines groups were equally effective in preventing symptomatic infections, and no life-threatening side effects were reported in either vaccine group.

show abstract

“…Severe post-vaccination adverse events were present in 0.25% (n = 9) of our population, in which ChAdOx1-S and Gam-COVID-Vac were more likely to develop such events. A previous report on 1954 healthcare workers showed a 0.4% (n = 9) severe post-vaccination adverse incident leading to hospital attendance; BIBP-CorV (n = 1), Gam-COVID-Vac V (n = 3), and ChAdOx1-S (n = 5) [21]. Overall, among vaccine recipients, adverse events were rare and non-lifethreatening.…”

Section: Discussionmentioning

confidence: 83%

COVID-19 vaccines breakthrough infection and adverse reactions in medical students: A nationwide survey in Iran

Allahgholipour

Rosstami-Nejad

Safavi-Naini

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose: This study aimed to investigate the rate of COVID-19 breakthrough infection and adverse events in medical students.Methods: Iranian medical students receiving two doses of COVID-19 vaccines were included in this retrospective cohort study. The medical team gathered the demographic characteristics, comorbidities, type of vaccine, adverse events following vaccination, and history of COVID-19 infection data through a phone interview. The frequency of adverse events and breakthrough infection was stratified by vaccine type (ChAdOx1-S, Gam-COVID-Vac, and BIBP-CorV).Results: A total of 3591 medical students enrolled in this study, of which 57.02% were females, with a mean age of 23.31 + 4.87. A PCR-confirmed and suspicious-for-COVID-19 breakthrough infection rate of 4.51% and 7.02% was detected, respectively. There was no significant relation between breakthrough infection and gender, BMI, blood groups, and comorbidities. However, there was a significant difference in breakthrough infection rate among different types of vaccines (P=0.001) and history of COVID-19 infection (P=0.001). A total of 16 participants were hospitalized for COVID-19 infection, and no severe infection or death was observed in the studied population.Conclusion: Vaccination prevented severe COVID-19 infection, although a high breakthrough infection rate was evident among Iran medical students during the Delta variant’s peak. Vaccine effectiveness may be fragile during emerging new variants and in high-exposure settings. Moreover, adverse events are rare, and the benefits of vaccination outweigh the side effects. However, many limitations challenged this study, and the results should be cautious.

show abstract

Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea

Cited by 20 publications

References 15 publications

More Than Three-Fourths of AstraZeneca (ChAdox1 COV-19) COVID-19 Vaccinated Individuals Develop Post Immunization Adverse Event in Northwest Ethiopia

More Than Three-Fourths of AstraZeneca (ChAdox1 COV-19) COVID-19 Vaccinated Individuals Develop Post Immunization Adverse Event in Northwest Ethiopia

Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers

COVID-19 vaccines breakthrough infection and adverse reactions in medical students: A nationwide survey in Iran

Contact Info

Product

Resources

About